The advent of DNA barcoding techniques speeded up the identification and characterization of new species and yielded many new insights. However, these techniques are not always applicable. For example, in most fossils DNA is not present and the Jurrasic Park techniques to dinosaur blood from a mosquito trapped in amber, still remains wishful thinking.
>Read more in Dutch
SkylineDx, an innovative company in the field of genetic testing for blood cancers, announced a strategic investment of an undisclosed sum in the Dutch cancer vaccine company DCPrime. The financing is designed to provide DCPrime with funding for the development of its technology platform and to take advantage of the synergies between the cancer companies.
Galapagos and Calchan collaborate on osteoarthritis research, £2.4 million grant awarded by Innovate UKPublished : Monday, October 27, 2014
Galapagos NV, a clinical stage biotech company focused on developing novel mode of action medicines, and Calchan Limited, a UK company focused on the development of novel medicines based on calcium ion channel modulators, announced that they have entered into a research collaboration in the area of osteoarthritis pain.
Leiden Bio Science Park foundation was present at the LUMC Science Day at October 26th. The very popular open day consists of a large fair with LUMC departments, all kind of tests and lectures.
Leiden Bio Science Park foundation organised 4 lectures that accompanied the viewing of the Red carpet (Rode Loper) films about the chain of drug development at Leiden Bio Science Park.
Beginning of October Thijs de Kleer, director and Ellen Smit, senior account manager, both of the Leiden Bio Science Park foundation visited Japan. During this trip, they visited life sciences companies including AnGes, Daiichi Sankyo and Maruho. A small seminar was organized by the Osaka Pharmaceutical Manufacturers Association where Leiden Bio Science Park was presented to life science companies in Osaka.
Galapagos discloses GPR84 as a promising novel target for treating inflammatory bowel disease during an oral presentation at United European Gastroenterology Week in Vienna on 21 October. Furthermore, Galapagos presents a poster disclosing favorable Phase 1 results with GLPG1205, the first clinical compound ever developed against target GPR84.
Drugs that will be developed in the future will increasingly affect pathophysiological pathways that have been largely unexplored. Such drug prototypes cannot immediately be introduced in large clinical trials, but require rational exploration in tailored early phase clinical studies, with biomarkers that are fit-to-purpose.
Treeway and LACDR at the University of Leiden join forces and form a collaboration focused on the optimization of clinical trial designs and data-analysis for ALS (Amyotrophic Lateral Sclerosis) through the use of population disease progression models. Furthermore both parties aim to obtain a better understanding of the disease by developing ALS physiology-based disease models and to test the effect of interventions in the different identified pathways.
Pluriomics announced that it has raised €4 million in a Series A round led by Vesalius Biocapital (VBC) with additional financing from InnovationQuarter (IQ) and Société régionale d'Investissement de Wallonie (SRIW).
The funds will be used to further develop Pluriomics’ innovative stem cell derived cardiomyocytes and assays and to commercialize these technologies. Pluriomics will strengthen its R&D and commercial team in Leiden while setting-up a production facility in Gosselies, thereby leveraging the expertise available in South Holland and Wallonia.
Biotech company Pharming Group NV and Swedish Orphan Biovitrum AB (publ) or “Sobi”, announced the amendment and extension of the Ruconest® distribution agreement between Pharming and Sobi. Effective immediately, Pharming will focus on direct commercialization in Austria, Germany and Netherlands, and Sobi will extend its Ruconest® sales territory with the addition of Azerbaijan, Belarus, Georgia, Kazakhstan, Russia, Serbia and Ukraine.
On October 10th he groundbreaking ceremony for the Biotech Training Facility (BTF) took place in Leiden at the Bio Science Park.This facility is aimed at the training of personnel for the biotechnology and the pharma industry. The BTF will be a real GMP production plant, where all unit operations that are important for the industry will be present. People can get the training they need there, in a standard series of courses or in tailor made training sessions.The first students can enter the BTF in Q4 2015.
Prosensa begins NDA submission to the FDA for exon-skipping drug drisapersen to treat Duchenne muscular dystrophyPublished : Friday, October 10, 2014
Prosensa Holding N.V. the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced that it has commenced the submission process for a New Drug Application (NDA) regulatory filing to the United States Food and Drug Administration (FDA) for its lead exon-skipping drug candidate, drisapersen, for treating Duchenne muscular dystrophy (DMD). The drug received "Fast Track status" from the FDA, making it eligible for a rolling review of an NDA and was also granted "Breakthrough Therapy Designation" in June 2013.
Dutch biotech MIMETAS B.V. announced that it has raised 5.2 million dollar to fund its expansion as a global leader in organ-on-a-chip technology. Venture capital investors Zeeuws Investerings Fonds (ZIF) and Participatiemaatschapij Oost Nederland (PPM Oost) have joined forces with national and regional partners to fund development and sales of MIMETAS’ unique 3D disease- and tissue modelling technologies.
LSP (Life Sciences Partners) announced that it has raised EUR 80 mln (USD 100 mln) for its new fund LSP 5. This fund will continue LSP’s proven and successful strategy of investing in emerging private companies with innovative medicines and medical technologies. Investors stated that they selected LSP because of its impact on healthcare and its consistently strong financial performance.
The Leiden Bio Science Park newsletter is a free bimonthly email newsletter in English. The newsletter offers general life science news, news from the companies and institutions, a company profile, events and jobs.
click here to subscribe